Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Euglycemic Diabetic Ketoacidosis in the Setting of Dulaglutide Use.

Patel N, Reddy A, Romero KN, Reddy P

Cureus12 Apr 2025Cited by 1 (Europe PMC)

PMID40357083 (opens in a new tab)PMCIDPMC12068660 (opens in a new tab)DOI10.7759/cureus.82143 (opens in a new tab)PepBankPUB-40357083
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Dulaglutide is a glucagon-like peptide (GLP-1) receptor agonist approved by the Food and Drug Administration in patients with type 2 diabetes mellitus (T2DM) with noted cardiovascular and renal benefits along with weight loss. Dulaglutide's most common adverse effects include fatigue, poor appetite, abdominal pain, nausea, vomiting, and diarrhea. Although typically associated with the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, there have been case reports of GLP-1 receptor agonists leading to euglycemic diabetic ketoacidosis (DKA). We present a case of dulaglutide use leading to euglycemic DKA, a rare but life-threatening adverse effect after re-initiation of the medication at a higher dose. Our patient presented with non-specific gastrointestinal symptoms and weakness, which both resolved after the initiation of an insulin drip and intravenous fluids.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A patient developed euglycemic diabetic ketoacidosis after restarting dulaglutide at a higher dose.

    In plain wordsOne patient developed ketoacidosis with normal blood sugar after restarting dulaglutide at a higher dose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableEuglycemic diabetic ketoacidosis
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present a case of dulaglutide use leading to euglycemic DKA, a rare but life-threatening adverse effect after re-initiation of the medication at a higher dose.
  2. 02HumanCase report or seriesSafety outcome

    A patient presented with non-specific gastrointestinal symptoms and weakness after dulaglutide re-initiation at a higher dose, and both resolved after an insulin drip and intravenous fluids.

    In plain wordsOne patient had stomach symptoms and weakness after dulaglutide was restarted at a higher dose. Both resolved with insulin and intravenous fluids.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNon-specific gastrointestinal symptoms and weakness at presentation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our patient presented with non-specific gastrointestinal symptoms and weakness, which both resolved after the initiation of an insulin drip and intravenous fluids.
    1 context sentence
    Summary · context
    We present a case of dulaglutide use leading to euglycemic DKA, a rare but life-threatening adverse effect after re-initiation of the medication at a higher dose.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.